CEL-SCI CORPORATION (CVM) Free cash flow
- Free cash flow · 12 months (USD): Value $-16.75M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $-16.75M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $-16.75M − $5.16K ≈ $-16.75M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | (m) | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-16.75M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 0.74× | Operating cash flow / net income. Period ending 2026-06-30. $-16.75M ÷ $-22.70M ≈ 0.74× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -16.75M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | 5.16K USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | -16.75M USD | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | (m) | |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -22.70M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $-16.75M | (m) | $-16.75M | $5.16K | (m) | (m) | (m) | $-22.70M | (m) | (m) | (m) | 0.74× |
| 2026-03-31 | $-16.66M | (m) | $-16.65M | $5.16K | (m) | (m) | (m) | $-22.70M | (m) | (m) | (m) | 0.73× |
| 2025-12-31 | $-17.01M | (m) | $-17.00M | $5.16K | (m) | (m) | (m) | $-23.81M | (m) | (m) | (m) | 0.71× |
| 2025-09-30 | $-17.16M | (m) | $-17.12M | $38.11K | (m) | (m) | (m) | $-25.41M | (m) | (m) | (m) | 0.67× |
| 2025-06-30 | $-17.32M | (m) | $-17.27M | $52.71K | (m) | (m) | (m) | $-26.08M | (m) | (m) | (m) | 0.66× |
| 2025-03-31 | $-17.98M | (m) | $-17.91M | $76.18K | (m) | (m) | (m) | $-27.27M | (m) | (m) | (m) | 0.66× |
| 2024-12-31 | $-18.14M | (m) | $-18.06M | $76.18K | (m) | (m) | (m) | $-27.94M | (m) | (m) | (m) | 0.65× |
| 2024-09-30 | $-18.91M | (m) | $-18.81M | $94.88K | (m) | (m) | (m) | $-27.58M | (m) | (m) | (m) | 0.68× |
| 2024-06-30 | $-19.11M | (m) | $-19.04M | $75.12K | (m) | (m) | (m) | $-28.44M | (m) | (m) | (m) | 0.67× |
| 2024-03-31 | $-20.37M | (m) | $-20.13M | $248.51K | (m) | (m) | (m) | $-29.95M | (m) | (m) | (m) | 0.67× |
| 2023-12-31 | $-23.43M | (m) | $-23.07M | $359.96K | (m) | (m) | (m) | $-31.05M | (m) | (m) | (m) | 0.74× |
| 2023-09-30 | $-23.21M | (m) | $-22.85M | $361.89K | (m) | (m) | (m) | $-32.19M | (m) | (m) | (m) | 0.71× |
| 2023-06-30 | $-23.10M | (m) | $-22.72M | $377.96K | (m) | (m) | (m) | $-33.03M | (m) | (m) | (m) | 0.69× |
| 2023-03-31 | $-23.09M | (m) | $-22.84M | $252.06K | (m) | (m) | (m) | $-34.29M | (m) | (m) | (m) | 0.67× |
| 2022-12-31 | $-18.78M | (m) | $-18.10M | $674.44K | (m) | (m) | (m) | $-35.77M | (m) | (m) | (m) | 0.51× |
| 2022-09-30 | $-18.88M | (m) | $-18.24M | $637.89K | (m) | (m) | (m) | $-36.70M | (m) | (m) | (m) | 0.50× |
| 2022-06-30 | $-19.14M | (m) | $-18.13M | $1.01M | (m) | (m) | (m) | $-36.44M | (m) | (m) | (m) | 0.50× |
| 2022-03-31 | $-20.48M | (m) | $-17.54M | $2.94M | (m) | (m) | (m) | $-35.75M | (m) | (m) | (m) | 0.49× |
| 2021-12-31 | $-25.65M | (m) | $-19.77M | $5.88M | (m) | (m) | (m) | $-37.21M | (m) | (m) | (m) | 0.53× |
| 2021-09-30 | $-27.80M | (m) | $-18.79M | $9.02M | (m) | (m) | (m) | $-36.36M | (m) | (m) | (m) | 0.52× |
| 2021-06-30 | $-22.01M | (m) | $-17.57M | $4.44M | (m) | (m) | (m) | $-33.54M | (m) | (m) | (m) | 0.52× |
| 2021-03-31 | $-19.29M | (m) | $-16.07M | $3.22M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-15.40M | (m) | $-15.00M | $393.09K | (m) | (m) | (m) | $-32.66M | (m) | (m) | (m) | 0.46× |
| 2020-09-30 | $-12.62M | (m) | $-15.28M | $-2.65M | (m) | (m) | (m) | $-30.26M | (m) | (m) | (m) | 0.50× |
| 2020-06-30 | $-14.40M | (m) | $-15.58M | $-1.18M | (m) | (m) | (m) | $-29.56M | (m) | (m) | (m) | 0.53× |
| 2020-03-31 | $-17.29M | (m) | $-16.52M | $769.66K | (m) | (m) | (m) | $-31.42M | (m) | (m) | (m) | 0.53× |
| 2019-12-31 | $-16.54M | (m) | $-16.26M | $273.47K | (m) | (m) | (m) | $-28.86M | (m) | (m) | (m) | 0.56× |
| 2019-09-30 | $-16.50M | (m) | $-16.32M | $177.78K | (m) | (m) | (m) | $-22.13M | (m) | (m) | (m) | 0.74× |
| 2019-06-30 | $-16.85M | (m) | $-16.68M | $171.32K | (m) | (m) | (m) | $-32.21M | (m) | (m) | (m) | 0.52× |
| 2019-03-31 | $-14.97M | (m) | $-14.81M | $161.94K | (m) | (m) | (m) | $-26.14M | (m) | (m) | (m) | 0.57× |
| 2018-12-31 | $-14.94M | (m) | $-14.93M | $7.15K | (m) | (m) | (m) | $-24.40M | (m) | (m) | (m) | 0.61× |
| 2018-09-30 | $-13.39M | (m) | $-13.39M | $1.01K | (m) | (m) | (m) | $-31.84M | (m) | (m) | (m) | 0.42× |
| 2018-06-30 | $-12.59M | (m) | $-12.59M | $1.01K | (m) | (m) | (m) | $-21.90M | (m) | (m) | (m) | 0.57× |
| 2018-03-31 | $-12.93M | (m) | $-12.93M | $0.00 | (m) | (m) | (m) | $-20.35M | (m) | (m) | (m) | 0.64× |
| 2017-12-31 | (m) | (m) | $-12.17M | (m) | (m) | (m) | (m) | $-24.07M | (m) | (m) | (m) | 0.51× |
| 2017-09-30 | $-13.80M | (m) | $-13.79M | $10.53K | (m) | (m) | (m) | $-14.36M | (m) | (m) | (m) | 0.96× |
| 2017-06-30 | $-17.22M | (m) | $-17.21M | $10.53K | (m) | (m) | (m) | $-10.43M | (m) | (m) | (m) | 1.65× |
| 2017-03-31 | $-19.53M | (m) | $-19.50M | $20.29K | (m) | (m) | (m) | $-9.84M | (m) | (m) | (m) | 1.98× |
| 2016-12-31 | $-21.50M | (m) | $-21.48M | $16.57K | (m) | (m) | (m) | $-10.27M | (m) | (m) | (m) | 2.09× |
| 2016-09-30 | $-23.11M | (m) | $-23.08M | $31.41K | (m) | (m) | (m) | $-11.47M | (m) | (m) | (m) | 2.01× |
| 2016-06-30 | $-21.61M | (m) | $-21.56M | $48.19K | (m) | (m) | (m) | $-20.20M | (m) | (m) | (m) | 1.07× |
| 2016-03-31 | $-22.43M | (m) | $-22.39M | $38.43K | (m) | (m) | (m) | $-20.78M | (m) | (m) | (m) | 1.08× |
| 2015-12-31 | $-24.30M | (m) | $-24.23M | $71.13K | (m) | (m) | (m) | $-24.49M | (m) | (m) | (m) | 0.99× |
| 2015-09-30 | $-23.91M | (m) | $-23.83M | $73.40K | (m) | (m) | (m) | $-34.67M | (m) | (m) | (m) | 0.69× |
| 2015-06-30 | $-24.31M | (m) | $-24.22M | $93.68K | (m) | (m) | (m) | $-32.05M | (m) | (m) | (m) | 0.76× |
| 2015-03-31 | $-24.13M | (m) | $-24.00M | $133.18K | (m) | (m) | (m) | $-30.07M | (m) | (m) | (m) | 0.80× |
| 2014-12-31 | $-22.56M | (m) | $-22.45M | $112.49K | (m) | (m) | (m) | $-30.88M | (m) | (m) | (m) | 0.73× |
| 2014-09-30 | $-23.03M | (m) | $-22.93M | $103.98K | (m) | $264.03K | (m) | $-27.37M | (m) | (m) | -8723.15% | 0.84× |
| 2014-06-30 | $-20.68M | (m) | $-20.60M | $75.53K | (m) | (m) | (m) | $-21.84M | (m) | (m) | (m) | 0.94× |
| 2014-03-31 | $-18.10M | (m) | $-18.05M | $52.62K | (m) | (m) | (m) | $-23.85M | (m) | (m) | (m) | 0.76× |
| 2013-12-31 | $-16.56M | (m) | $-16.47M | $94.53K | (m) | (m) | (m) | $-11.20M | (m) | (m) | (m) | 1.47× |
| 2013-09-30 | $-13.65M | (m) | $-13.55M | $102.03K | (m) | $159.58K | (m) | $-9.17M | (m) | (m) | -8553.93% | 1.48× |
| 2013-06-30 | $-13.52M | (m) | $-13.41M | $104.83K | (m) | (m) | (m) | $-10.04M | (m) | (m) | (m) | 1.34× |
| 2013-03-31 | $-13.17M | (m) | $-13.07M | $100.66K | (m) | (m) | (m) | $-6.43M | (m) | (m) | (m) | 2.03× |
| 2012-12-31 | $-12.63M | (m) | $-12.57M | $54.26K | (m) | (m) | (m) | $-14.21M | (m) | (m) | (m) | 0.89× |
| 2012-09-30 | $-12.24M | (m) | $-12.19M | $54.64K | (m) | $254.61K | (m) | $-15.48M | (m) | (m) | -4809.18% | 0.79× |
| 2012-06-30 | $-13.40M | (m) | $-13.75M | $-348.53K | (m) | (m) | (m) | $-15.23M | (m) | (m) | (m) | 0.90× |
| 2012-03-31 | $-17.52M | (m) | $-17.80M | $-282.54K | (m) | (m) | (m) | $-17.51M | (m) | (m) | (m) | 1.02× |
| 2011-12-31 | $-18.50M | (m) | $-18.73M | $-228.03K | (m) | (m) | (m) | $-23.04M | (m) | (m) | (m) | 0.81× |
| 2011-09-30 | $-22.34M | (m) | $-22.56M | $-216.76K | (m) | (m) | (m) | $-25.71M | (m) | (m) | (m) | 0.88× |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-09-30 | $-12.31M | (m) | $-12.80M | $-493.74K | (m) | (m) | (m) | $10.48M | (m) | (m) | (m) | -1.22× |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-09-30 | $-6.32M | (m) | $-6.51M | $-191.87K | (m) | (m) | (m) | $-40.91M | (m) | (m) | (m) | 0.16× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |